title: In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins.
abstract: The influence of intravenous infusions of various prostaglandins on in vivo platelet function was studied after labelling of autologous platelets with 100 mu ci 111 indium-oxinesulfate in patients with peripheral vascular disease stage II according to FONTAINE. PGI2 (5 ng/kg/min) provoked a significant decrease of platelet deposition and a prolongation in platelet half-life time (74 +/- 6 vs 68 +/- 5 hours). PGE1 (25 ng/kg/min) failed to influence platelet deposition, but prolonged significantly platelet half-life time (82 +/- 6 vs 76 +/- 8 hours). CG 4203 (25 ng/kg/min) decreased significantly platelet deposition and prolonged significantly platelet half-life time (73 +/- 10 vs 67 +/- 11 hours). Iloprost (1 and 2 ng/kg/min) reduced significantly platelet deposition without dose relation. Half-life time was increased significantly after therapy compared to placebo (1 ng: 76 +/- 7 vs 69 +/- 7; 2 ng: 73 +/- 9 vs 67 +/- 9 hours).
authors: 2nd Department of Internal Medicine, University of Vienna, Austria.
authors: P
authors: P
authors: Fitscha
authors: J
authors: J
authors: Kaliman
authors: J
authors: J
authors: O'Grady
authors: H
authors: H
authors: Sinzinger
mesh_terms: D000368:Aged; D000527:Alprostadil / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000097:blood / Q000503:physiopathology*; D002317:Cardiovascular Agents / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology* / Q000031:analogs & derivatives; D006801:Humans; D016285:Iloprost; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*
chemical_list: D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors; C039188:taprostene; D011464:Epoprostenol; D000527:Alprostadil; D016285:Iloprost